$DYAI Dyadic Announces Second Quarter 2024 Financi
Post# of 24949
Alternative Proteins
Entered into a development and commercialization partnership for the sale of animal-free recombinant albumin products with Proliant Health and Biologicals
Entered into a joint development agreement with a Top 10 global dairy company for the development of non-animal alpha-lactalbumin
Ongoing development of a robust pipeline of non-pharmaceutical recombinant product candidates such as alpha-lactalbumin, transferrin, DNASE-1, and several potential biofuels and other enzymes utilizing the Dapibus™ platform technology
Animal Health
Provided samples of the C1-produced recombinant ferritin nanoparticle H5 Clade 2.3.3.4.b A/Astrakhan avian influenza ‘Bird Flu‘ antigen to multiple parties for evaluation and potential use in poultry and cattle vaccines
Initiated analysis of additional targets for expanded collaboration with Phibro/Abic to develop vaccines and treatments for livestock animal diseases
https://dyadic.com/dyadic-announces-second-qu...-progress/